Efficacy, safety and biomarkers of SG001 for patients with previously treated recurrent or metastatic cervical cancer: an open-label, multicenter, phase Ib trial

Jing Zuo; Wei Duan; Mingxuan Zhao; Zhendong Chen; Jie Lin; Huaqiu Shi; Ou Jiang; Youzhong Zhang; Meiyu Fang; Li Wang; Wei Wang; Yong Huang; Junyan Yu; Xiaoxue Zhang; Weiqing Pu; Deshun Hao; Fenglin She; Xiugao Yang; Ying Chen; Qizhi Tang; Xiao Zhang; Miao Niu; Yan’e Song; Lingying Wu

doi:10.1002/cac2.12578

Cancer Communications ›› 2024, Vol. 44 ›› Issue (09) : 1042 -1046. DOI: 10.1002/cac2.12578

LETTER TO THE JOURNAL

Efficacy, safety and biomarkers of SG001 for patients with previously treated recurrent or metastatic cervical cancer: an open-label, multicenter, phase Ib trial

Author information +

¹. Department of Gynecology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China

². Department of Gynecology and Oncology, Beijing Obstetrics and Gynecology Hospital, Beijing, P. R. China

³. Phase 1 Clinical Trial Center, Anning First People’s Hospital, Anning, Yunnan, P. R. China

⁴. Department of Oncology, The Second Hospital of Anhui Medical University, Hefei, Anhui, P. R. China

⁵. Department of Oncology, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, P. R. China

⁶. Department of Oncology, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, P. R. China

⁷. Department of Medical Oncology, The Second People’s Hospital of Neijiang, Neijiang, Sichuan, P. R. China

⁸. Department of Gynecology, Qilu Hospital of Shandong University, Jinan, Shandong, P. R. China

⁹. Department of Rare and Head and Neck Oncology, Cancer Hospital of The University of Chinese Academy of Sciences Zhejiang Cancer Hospital, Hangzhou, Zhejiang, P. R. China

¹⁰. Department of Gynecology, Henan Cancer Hospital, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, P. R. China

¹¹. Department of Gastroenterology and Urology, Hunan Cancer Hospital, Changsha, Hunan, P. R. China

¹². Department of Oncology, The Second People’s Hospital of Hefei, Hefei, Anhui, P. R. China

¹³. Department of Oncology, Heping Hospital Affiliated to Changzhi Medical College, Changzhi, Shanxi, P. R. China

¹⁴. Clinical Development Division, CSPC Pharmaceutical Group Co., Ltd. Shijiazhuang, Hebei, P. R. China

wulingying@csco.org.cn

Show less

History +

PDF

Cite this article

Download citation ▾

Jing Zuo, Wei Duan, Mingxuan Zhao, Zhendong Chen, Jie Lin, Huaqiu Shi, Ou Jiang, Youzhong Zhang, Meiyu Fang, Li Wang, Wei Wang, Yong Huang, Junyan Yu, Xiaoxue Zhang, Weiqing Pu, Deshun Hao, Fenglin She, Xiugao Yang, Ying Chen, Qizhi Tang, Xiao Zhang, Miao Niu, Yan’e Song, Lingying Wu. Efficacy, safety and biomarkers of SG001 for patients with previously treated recurrent or metastatic cervical cancer: an open-label, multicenter, phase Ib trial. Cancer Communications, 2024, 44(09): 1042-1046 DOI:10.1002/cac2.12578

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3): 209–249.

[2]	Cheng M, Wang H, Zhao Y, Li G. Efficacy and Prognostic Factors for Response to PD-1 Inhibitors in Advanced Cervical Carcinoma: A Retrospective Study. Drug Des Dev Ther. 2022; 16: 887–897.

[3]	Colombo N, Dubot C, Lorusso D, Caceres MV, Hasegawa K, Shapira-Frommer R. et al. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. N Engl J Med. 2021; 385(20): 1856–1867.

[4]	Naumann RW, Hollebecque A, Meyer T, Devlin M-J, Oaknin A, Kerger J, et al. Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial. J Clin Oncol. 2019; 37(31): 2825–2834.

[5]	Chung HC, Ros W, Delord J-P, Perets R, Italiano A, Shapira-Frommer R. et al. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2019; 37(17): 1470–1478.

[6]	O’Malley DM, Oaknin A, Monk BJ, Selle F, Rojas C, Gladieff L, et al. Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer. Gynecol Oncol. 2021; 163(2): 274–280.

[7]	Chung H, Delord J-P, Perets R, Italiano A, Shapira-Frommer R. Manzuk L, et al. Pembrolizumab treatment of advanced cervical cancer: updated results from the phase II KEYNOTE-158 study. Gynecol Oncol. 2021; 162: S27.

[8]

Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R. Nakagawa K, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020; 21(10): 1353–1365.

[9]	Huang X, He M, Peng H, Tong C, Liu Z, Zhang X, et al. Genomic profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: a secondary analysis of the CLAP trial. J Immunother Cancer. 2021; 9(5): e002223.

[10]	Frenel J-S, Le Tourneau C, O’Neil B, Ott PA, Piha-Paul SA. Gomez-Roca C, et al. Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1–Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial. J Clin Oncol. 2017; 35(36): 4035–4041.